## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.4% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. CVS Forecasts 2026 Revenue Short of Wall Street Estimates**
- Source: Bloomberg.com | 20251209T113000 | Neutral | Relevance: 99%
- CVS Health Corp. has provided 2026 revenue guidance of at least $400 billion, falling short of Wall Street's average estimate of $418.3 billion. The company is facing a challenging retail environment and increased government scrutiny within the healthcare sector. However, its adjusted earnings forecast of up to $7.20 per share for 2026 surpassed analyst expectations.

**2. CVS raises profit forecast as turnaround plan takes effect**
- Source: Honolulu Star-Advertiser | 20251209T000556 | Bullish | Relevance: 99%
-  CVS Health has raised its 2025 profit forecast for the fourth time, signaling steady progress in its turnaround plan and prompting a 2.2% rise in its shares. The company's CEO, David Joyner, highlighted investments in building trust and improving consumer experiences, including the launch of a new consumer app. Despite forecasting 2026 revenue below analyst expectations, CVS anticipates strong earnings growth, driven by its Aetna insurance business and CVS Caremark pharmacy benefit management unit.

**3. CVS Health (NYSE: CVS) offers MMR vaccines in South Carolina amid measles outbreak**
- Source: Stock Titan | 20251211T160753 | Neutral | Relevance: 99%
-  CVS Health (NYSE: CVS) is providing measles-mumps-rubella (MMR) vaccines at over 200 CVS Pharmacy and MinuteClinic locations across South Carolina to address a current measles outbreak. This initiative allows walk-ins, with appointments encouraged, and targets patients aged 3 and older, including a recommended second dose for children aged 4-6 at MinuteClinic. The company also announced an investor day event and positive financial guidance for 2025, highlighting its strategic initiatives alongside public health efforts.

**4. CVS boosts profit outlook in sign of momentum as 2026 nears**
- Source: The Boston Globe | 20251209T222001 | Bullish | Relevance: 99%
-  CVS Health Corp. has raised its full-year profit forecast for 2025 and provided an optimistic outlook for 2026, signaling momentum despite a challenging retail and healthcare environment. The company adjusted its expected adjusted earnings per share for 2026 to $7.20, slightly above analyst expectations, and increased its 2025 profit forecast by 5 cents to $6.60-$6.70 per share. This positive guidance reflects CVS's strategy to navigate government scrutiny and evolving industry practices across its health insurance, drug benefit management, and retail pharmacy segments.

**5. CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak**
- Source: Financial Times | 20251211T163217 | Bullish | Relevance: 98%
- CVS Health is offering the measles-mumps-rubella (MMR) vaccine at its CVS Pharmacy and MinuteClinic locations in South Carolina due to a current measles outbreak in the state. The vaccine is available to residents aged three and older at CVS Pharmacy, while MinuteClinic provides the second vaccination dose to children aged 4-6. This initiative aims to help protect the public from the highly contagious disease, with both walk-ins and scheduled appointments encouraged.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 8, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |
| 2025-12-10 | UBS | $97 | $96 | +1% |
| 2025-12-10 | Barclays | $93 | $87 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-12-10 | UBS | main | Buy |
| 2025-12-10 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 8 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +6.8% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.67 indicates undervaluation relative to growth. Analyst sentiment positive (8 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.6B |
| Beta | 0.48 |
| 52W Range | $43.56 - $85.15 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.67 |
| Forward P/E | 11.3 |
| Current P/E | 12.1 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.3% to 1.4% (+6.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 at 3.6% confirms short-term momentum alignment. AM_20 at 3.7% shows strong absolute momentum above own 20MA. Outperforming sector by 3.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. Elevated volume (1.7x 20MA), institutional activity likely.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.45% (CS: 55) | Neutral |
| RSI_14 | 58.6 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 1.155x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.83
- **Stop Loss:** $76.61 (5.2% risk)
- **Target:** $85.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 327
- **Position Value:** $26,431.41
- **Portfolio %:** 26.43%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*